neurofibromatosis type 1
Showing 1 - 25 of 63
FARD (RaDiCo Cohort) (RaDiCo-FARD)
Recruiting
- Inherited Epidermolysis Bullosa
- +8 more
-
Bobigny, France
- +14 more
Jul 18, 2023
Neurofibromatosis Type 1, Plexiform Neurofibromas, Post-operative Trial in Beijing, Shanghai (Selumetinib, Placebo)
Not yet recruiting
- Neurofibromatosis Type 1
- +2 more
- Selumetinib
- Placebo
-
Beijing, China
- +2 more
Apr 11, 2023
Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma Trial in Worldwide (dabrafenib, trametinib)
Recruiting
- Diffuse Astrocytoma
- +22 more
-
Phoenix, Arizona
- +26 more
Jan 27, 2023
Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Visual Pathway Glioma Trial in
Active, not recruiting
- Neurofibromatosis Type 1
- +2 more
- Lenalidomide
- Pharmacological Study
-
Birmingham, Alabama
- +125 more
Jan 25, 2023
Data Collected From Individuals Administered Neurobehavioral
Enrolling by invitation
- HIV
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 25, 2023
Biology of Skin Neurofibromas in Neurofibromatosis Type 1
Completed
- Neurofibromatosis Type 1
- Neurofibroma
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
US Selumetinib Registry
Not yet recruiting
- Neurofibromatosis Type 1
- Plexiform Neurofibromas
- (no location specified)
Jan 5, 2023
PASS of Paediatric Patients Initiating Selumetinib
Recruiting
- Neurofibromatosis Type 1
-
Angers, France
- +3 more
Jan 12, 2023
Neurofibromatosis Type 1 Trial in Worldwide (Selumetinib)
Active, not recruiting
- Neurofibromatosis Type 1
-
Rochester, Minnesota
- +8 more
Nov 10, 2022
Cutaneous Neurofibromas in People With NF1
Recruiting
- Neurofibromatosis Type 1
- +3 more
- Evaluation of the natural history of cutaneous neurofibromas
-
Baltimore, MarylandJohns Hopkins University
Oct 12, 2022
Frameshift Peptides of Children With NF1
Completed
- Neurofibromatosis Type 1
- Frameshift Array blood sample test
-
Washington, District of Columbia
- +2 more
Aug 29, 2022
Neurofibromatosis 1, Neurofibromatosis Type 1, NF1 Trial run by the National Cancer Institute (NCI) (AZD6244)
Active, not recruiting
- Neurofibromatosis 1
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022
Neurofibromatosis Type 1 Trial in Worldwide (Selumetinib granule formulation, Selumetinib capsule formulation)
Recruiting
- Neurofibromatosis Type 1
- Selumetinib granule formulation
- Selumetinib capsule formulation
-
Phoenix, Arizona
- +17 more
Aug 4, 2022
Neurofibromatosis Type 1 Trial in Los Angeles (Whole-body Magnetic Resonance Imaging)
Recruiting
- Neurofibromatosis Type 1
- Whole-body Magnetic Resonance Imaging
-
Los Angeles, CaliforniaCedars Sinai Medical Center
Jul 11, 2022
Metastatic Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1, Recurrent Malignant Peripheral Nerve Sheath Tumor
Recruiting
- Metastatic Malignant Peripheral Nerve Sheath Tumor
- +2 more
- Computed Tomography
- +4 more
-
Rochester, MinnesotaMayo Clinic
Jul 6, 2022
Familial Investigations of Childhood Cancer Predisposition
Recruiting
- Acute Leukemia
- +45 more
-
Memphis, TennesseeSt. Jude Children's Research Hospital
May 11, 2022
Neurofibromatosis Type 1, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Visual Pathway Glioma Trial in United
Completed
- Neurofibromatosis Type 1
- +4 more
- Laboratory Biomarker Analysis
- +2 more
-
Los Angeles, California
- +11 more
Apr 22, 2022
Neurofibromatosis 1, NF1, Neurofibromatosis Type 1 Trial in Chicago
Recruiting
- Neurofibromatosis 1
- +2 more
-
Chicago, IllinoisAnn & Robert H. Lurie Children's Hospital of Chicago
Mar 11, 2022
Stem Cells in NF1 Tumors of the Central Nervous System
Suspended
- Neurofibromatosis Type 1
- Tumors of the Central Nervous System
- Collection of Stem Cells
-
Washington, District of ColumbiaChildren's National Medical Center
Mar 8, 2022
Neurofibromatosis Type 1 Trial in Washington (CogmedRM, Mobymax)
Completed
- Neurofibromatosis Type 1
- CogmedRM
- Mobymax
-
Washington, District of ColumbiaChildren's National Health System
Mar 2, 2022
Measures in Neurofibromatosis 1: Test- Retest
Suspended
- Neurofibromatosis Type 1
- Outcome measures
-
London, United KingdomGuy's Hospital
Dec 23, 2021
Molecular Aspects of Preimplantation Genetic Diagnosis for NF1
Recruiting
- Neurofibromatosis Type 1
-
Strasbourg, FranceService Laboratoire de Diagnostic Génétique - Hôpitaux Universit
Nov 24, 2021
Neurofibromatosis Type 1, Plexiform Neurofibroma Trial in United States (Binimetinib)
Active, not recruiting
- Neurofibromatosis Type 1
- Plexiform Neurofibroma
-
Birmingham, Alabama
- +21 more
Dec 4, 2021